Close

Vertex Pharma (VRTX): Cutting PT On Slower Orkambi Uptake - Baird

September 29, 2016 6:29 AM EDT Send to a Friend
Baird analyst, Brian Skorney, reiterated his Neutral rating on shares of Vertex (NASDAQ: VRTX) and cut the price target to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login